cdm_name,result_type,group_name,group_level,strata_name,strata_level,variable,variable_level,variable_type,estimate_type,estimate
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,number subjects,NA,numeric,count,60032
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,number records,NA,NA,count,60032
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,alirocumab,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,alirocumab,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,fluvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,fluvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,lovastatin,0 to 0,binary,count,7
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,lovastatin,0 to 0,binary,percentage,0.011660447761194
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,pitavastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,pitavastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,ezetimibe,0 to 0,binary,count,824
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,ezetimibe,0 to 0,binary,percentage,1.3726012793177
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,rosuvastatin,0 to 0,binary,count,26
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,rosuvastatin,0 to 0,binary,percentage,0.0433102345415778
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,atorvastatin,0 to 0,binary,count,84
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,atorvastatin,0 to 0,binary,percentage,0.139925373134328
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,pravastatin,0 to 0,binary,count,17
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,pravastatin,0 to 0,binary,percentage,0.0283182302771855
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,evolocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,evolocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,cerivastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,cerivastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,unexposed,0 to 0,binary,count,59075
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,unexposed,0 to 0,binary,percentage,98.4058502132196
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,atorvastatin,1 to 30,binary,count,732
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,atorvastatin,1 to 30,binary,percentage,1.21934968017058
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,evolocumab,1 to 30,binary,count,18
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,evolocumab,1 to 30,binary,percentage,0.0299840085287846
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,alirocumab,1 to 30,binary,count,5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,alirocumab,1 to 30,binary,percentage,0.00832889125799574
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,rosuvastatin,1 to 30,binary,count,342
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,rosuvastatin,1 to 30,binary,percentage,0.569696162046908
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,pravastatin,1 to 30,binary,count,183
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,pravastatin,1 to 30,binary,percentage,0.304837420042644
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,lovastatin,1 to 30,binary,count,48
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,lovastatin,1 to 30,binary,percentage,0.0799573560767591
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,pitavastatin,1 to 30,binary,count,20
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,pitavastatin,1 to 30,binary,percentage,0.0333155650319829
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,ezetimibe,1 to 30,binary,count,393
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,ezetimibe,1 to 30,binary,percentage,0.654650852878465
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,fluvastatin,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,fluvastatin,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,cerivastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,cerivastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,unexposed,1 to 30,binary,count,58329
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,unexposed,1 to 30,binary,percentage,97.1631796375267
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,alirocumab,31 to 90,binary,count,7
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,alirocumab,31 to 90,binary,percentage,0.011660447761194
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,atorvastatin,31 to 90,binary,count,1220
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,atorvastatin,31 to 90,binary,percentage,2.03224946695096
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,rosuvastatin,31 to 90,binary,count,513
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,rosuvastatin,31 to 90,binary,percentage,0.854544243070362
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,evolocumab,31 to 90,binary,count,35
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,evolocumab,31 to 90,binary,percentage,0.0583022388059702
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,pravastatin,31 to 90,binary,count,293
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,pravastatin,31 to 90,binary,percentage,0.48807302771855
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,pitavastatin,31 to 90,binary,count,25
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,pitavastatin,31 to 90,binary,percentage,0.0416444562899787
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,lovastatin,31 to 90,binary,count,89
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,lovastatin,31 to 90,binary,percentage,0.148254264392324
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,fluvastatin,31 to 90,binary,count,5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,fluvastatin,31 to 90,binary,percentage,0.00832889125799574
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,ezetimibe,31 to 90,binary,count,669
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,ezetimibe,31 to 90,binary,percentage,1.11440565031983
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,cerivastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,cerivastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,unexposed,31 to 90,binary,count,57241
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,unexposed,31 to 90,binary,percentage,95.3508128997868
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,lovastatin,91 to 180,binary,count,96
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,lovastatin,91 to 180,binary,percentage,0.159914712153518
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,rosuvastatin,91 to 180,binary,count,867
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,rosuvastatin,91 to 180,binary,percentage,1.44422974413646
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,alirocumab,91 to 180,binary,count,10
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,alirocumab,91 to 180,binary,percentage,0.0166577825159915
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,fluvastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,fluvastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,ezetimibe,91 to 180,binary,count,771
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,ezetimibe,91 to 180,binary,percentage,1.28431503198294
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,evolocumab,91 to 180,binary,count,58
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,evolocumab,91 to 180,binary,percentage,0.0966151385927505
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,pitavastatin,91 to 180,binary,count,40
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,pitavastatin,91 to 180,binary,percentage,0.0666311300639659
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,pravastatin,91 to 180,binary,count,410
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,pravastatin,91 to 180,binary,percentage,0.68296908315565
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,atorvastatin,91 to 180,binary,count,1803
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,atorvastatin,91 to 180,binary,percentage,3.00339818763326
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,cerivastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,cerivastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,unexposed,91 to 180,binary,count,56081
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,unexposed,91 to 180,binary,percentage,93.4185101279318
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,lovastatin,181 to 365,binary,count,104
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,lovastatin,181 to 365,binary,percentage,0.173240938166311
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,pitavastatin,181 to 365,binary,count,43
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,pitavastatin,181 to 365,binary,percentage,0.0716284648187633
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,ezetimibe,181 to 365,binary,count,845
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,ezetimibe,181 to 365,binary,percentage,1.40758262260128
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,rosuvastatin,181 to 365,binary,count,1322
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,rosuvastatin,181 to 365,binary,percentage,2.20215884861407
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,evolocumab,181 to 365,binary,count,80
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,evolocumab,181 to 365,binary,percentage,0.133262260127932
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,alirocumab,181 to 365,binary,count,15
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,alirocumab,181 to 365,binary,percentage,0.0249866737739872
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,fluvastatin,181 to 365,binary,count,7
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,fluvastatin,181 to 365,binary,percentage,0.011660447761194
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,atorvastatin,181 to 365,binary,count,2742
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,atorvastatin,181 to 365,binary,percentage,4.56756396588486
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,pravastatin,181 to 365,binary,count,523
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,pravastatin,181 to 365,binary,percentage,0.871202025586354
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,cerivastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,cerivastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,unexposed,181 to 365,binary,count,54584
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,Overall,Overall,unexposed,181 to 365,binary,percentage,90.9248400852878
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,number subjects,NA,numeric,count,253
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,number records,NA,NA,count,253
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,alirocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,alirocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,fluvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,fluvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,lovastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,lovastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,pitavastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,pitavastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,ezetimibe,0 to 0,binary,count,8
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,ezetimibe,0 to 0,binary,percentage,3.16205533596838
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,rosuvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,rosuvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,atorvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,atorvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,pravastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,pravastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,evolocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,evolocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,cerivastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,cerivastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,unexposed,0 to 0,binary,count,245
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,unexposed,0 to 0,binary,percentage,96.8379446640316
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,atorvastatin,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,atorvastatin,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,evolocumab,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,evolocumab,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,alirocumab,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,alirocumab,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,rosuvastatin,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,rosuvastatin,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,pravastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,pravastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,lovastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,lovastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,pitavastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,pitavastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,ezetimibe,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,ezetimibe,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,fluvastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,fluvastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,cerivastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,cerivastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,unexposed,1 to 30,binary,count,246
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,unexposed,1 to 30,binary,percentage,97.2332015810277
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,alirocumab,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,alirocumab,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,atorvastatin,31 to 90,binary,count,5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,atorvastatin,31 to 90,binary,percentage,1.97628458498024
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,rosuvastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,rosuvastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,evolocumab,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,evolocumab,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,pravastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,pravastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,pitavastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,pitavastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,lovastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,lovastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,fluvastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,fluvastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,ezetimibe,31 to 90,binary,count,5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,ezetimibe,31 to 90,binary,percentage,1.97628458498024
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,cerivastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,cerivastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,unexposed,31 to 90,binary,count,238
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,unexposed,31 to 90,binary,percentage,94.0711462450593
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,lovastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,lovastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,rosuvastatin,91 to 180,binary,count,6
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,rosuvastatin,91 to 180,binary,percentage,2.37154150197628
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,alirocumab,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,alirocumab,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,fluvastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,fluvastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,ezetimibe,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,ezetimibe,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,evolocumab,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,evolocumab,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,pitavastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,pitavastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,pravastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,pravastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,atorvastatin,91 to 180,binary,count,6
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,atorvastatin,91 to 180,binary,percentage,2.37154150197628
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,cerivastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,cerivastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,unexposed,91 to 180,binary,count,238
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,unexposed,91 to 180,binary,percentage,94.0711462450593
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,lovastatin,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,lovastatin,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,pitavastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,pitavastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,ezetimibe,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,ezetimibe,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,rosuvastatin,181 to 365,binary,count,7
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,rosuvastatin,181 to 365,binary,percentage,2.76679841897233
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,evolocumab,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,evolocumab,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,alirocumab,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,alirocumab,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,fluvastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,fluvastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,atorvastatin,181 to 365,binary,count,6
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,atorvastatin,181 to 365,binary,percentage,2.37154150197628
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,pravastatin,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,pravastatin,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,cerivastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,cerivastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,unexposed,181 to 365,binary,count,237
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,0 to 19,unexposed,181 to 365,binary,percentage,93.6758893280632
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,number subjects,NA,numeric,count,2841
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,number records,NA,NA,count,2841
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,alirocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,alirocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,fluvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,fluvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,lovastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,lovastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,pitavastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,pitavastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,ezetimibe,0 to 0,binary,count,42
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,ezetimibe,0 to 0,binary,percentage,1.47835269271383
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,rosuvastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,rosuvastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,atorvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,atorvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,pravastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,pravastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,evolocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,evolocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,cerivastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,cerivastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,unexposed,0 to 0,binary,count,2798
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,unexposed,0 to 0,binary,percentage,98.4864484336501
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,atorvastatin,1 to 30,binary,count,25
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,atorvastatin,1 to 30,binary,percentage,0.879971840901091
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,evolocumab,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,evolocumab,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,alirocumab,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,alirocumab,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,rosuvastatin,1 to 30,binary,count,11
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,rosuvastatin,1 to 30,binary,percentage,0.38718760999648
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,pravastatin,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,pravastatin,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,lovastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,lovastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,pitavastatin,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,pitavastatin,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,ezetimibe,1 to 30,binary,count,19
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,ezetimibe,1 to 30,binary,percentage,0.668778599084829
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,fluvastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,fluvastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,cerivastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,cerivastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,unexposed,1 to 30,binary,count,2781
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,unexposed,1 to 30,binary,percentage,97.8880675818374
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,alirocumab,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,alirocumab,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,atorvastatin,31 to 90,binary,count,33
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,atorvastatin,31 to 90,binary,percentage,1.16156282998944
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,rosuvastatin,31 to 90,binary,count,13
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,rosuvastatin,31 to 90,binary,percentage,0.457585357268567
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,evolocumab,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,evolocumab,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,pravastatin,31 to 90,binary,count,7
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,pravastatin,31 to 90,binary,percentage,0.246392115452306
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,pitavastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,pitavastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,lovastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,lovastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,fluvastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,fluvastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,ezetimibe,31 to 90,binary,count,31
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,ezetimibe,31 to 90,binary,percentage,1.09116508271735
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,cerivastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,cerivastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,unexposed,31 to 90,binary,count,2752
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,unexposed,31 to 90,binary,percentage,96.8673002463921
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,lovastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,lovastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,rosuvastatin,91 to 180,binary,count,25
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,rosuvastatin,91 to 180,binary,percentage,0.879971840901091
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,alirocumab,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,alirocumab,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,fluvastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,fluvastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,ezetimibe,91 to 180,binary,count,32
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,ezetimibe,91 to 180,binary,percentage,1.1263639563534
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,evolocumab,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,evolocumab,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,pitavastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,pitavastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,pravastatin,91 to 180,binary,count,12
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,pravastatin,91 to 180,binary,percentage,0.422386483632524
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,atorvastatin,91 to 180,binary,count,50
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,atorvastatin,91 to 180,binary,percentage,1.75994368180218
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,cerivastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,cerivastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,unexposed,91 to 180,binary,count,2717
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,unexposed,91 to 180,binary,percentage,95.6353396691306
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,lovastatin,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,lovastatin,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,pitavastatin,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,pitavastatin,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,ezetimibe,181 to 365,binary,count,26
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,ezetimibe,181 to 365,binary,percentage,0.915170714537135
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,rosuvastatin,181 to 365,binary,count,48
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,rosuvastatin,181 to 365,binary,percentage,1.68954593453009
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,evolocumab,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,evolocumab,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,alirocumab,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,alirocumab,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,fluvastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,fluvastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,atorvastatin,181 to 365,binary,count,87
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,atorvastatin,181 to 365,binary,percentage,3.0623020063358
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,pravastatin,181 to 365,binary,count,22
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,pravastatin,181 to 365,binary,percentage,0.77437521999296
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,cerivastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,cerivastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,unexposed,181 to 365,binary,count,2657
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,20 to 39,unexposed,181 to 365,binary,percentage,93.523407250968
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,number subjects,NA,numeric,count,22338
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,number records,NA,NA,count,22338
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,alirocumab,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,alirocumab,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,fluvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,fluvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,lovastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,lovastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,pitavastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,pitavastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,ezetimibe,0 to 0,binary,count,242
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,ezetimibe,0 to 0,binary,percentage,1.08335571671591
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,rosuvastatin,0 to 0,binary,count,7
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,rosuvastatin,0 to 0,binary,percentage,0.031336735607485
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,atorvastatin,0 to 0,binary,count,33
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,atorvastatin,0 to 0,binary,percentage,0.147730325006715
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,pravastatin,0 to 0,binary,count,5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,pravastatin,0 to 0,binary,percentage,0.022383382576775
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,evolocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,evolocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,cerivastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,cerivastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,unexposed,0 to 0,binary,count,22049
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,unexposed,0 to 0,binary,percentage,98.7062404870624
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,atorvastatin,1 to 30,binary,count,229
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,atorvastatin,1 to 30,binary,percentage,1.0251589220163
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,evolocumab,1 to 30,binary,count,7
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,evolocumab,1 to 30,binary,percentage,0.031336735607485
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,alirocumab,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,alirocumab,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,rosuvastatin,1 to 30,binary,count,136
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,rosuvastatin,1 to 30,binary,percentage,0.60882800608828
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,pravastatin,1 to 30,binary,count,58
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,pravastatin,1 to 30,binary,percentage,0.25964723789059
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,lovastatin,1 to 30,binary,count,10
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,lovastatin,1 to 30,binary,percentage,0.04476676515355
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,pitavastatin,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,pitavastatin,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,ezetimibe,1 to 30,binary,count,136
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,ezetimibe,1 to 30,binary,percentage,0.60882800608828
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,fluvastatin,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,fluvastatin,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,cerivastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,cerivastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,unexposed,1 to 30,binary,count,21770
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,unexposed,1 to 30,binary,percentage,97.4572477392784
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,alirocumab,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,alirocumab,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,atorvastatin,31 to 90,binary,count,409
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,atorvastatin,31 to 90,binary,percentage,1.8309606947802
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,rosuvastatin,31 to 90,binary,count,194
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,rosuvastatin,31 to 90,binary,percentage,0.86847524397887
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,evolocumab,31 to 90,binary,count,9
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,evolocumab,31 to 90,binary,percentage,0.040290088638195
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,pravastatin,31 to 90,binary,count,89
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,pravastatin,31 to 90,binary,percentage,0.398424209866595
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,pitavastatin,31 to 90,binary,count,8
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,pitavastatin,31 to 90,binary,percentage,0.03581341212284
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,lovastatin,31 to 90,binary,count,12
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,lovastatin,31 to 90,binary,percentage,0.05372011818426
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,fluvastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,fluvastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,ezetimibe,31 to 90,binary,count,208
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,ezetimibe,31 to 90,binary,percentage,0.93114871519384
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,cerivastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,cerivastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,unexposed,31 to 90,binary,count,21423
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,unexposed,31 to 90,binary,percentage,95.9038409884502
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,lovastatin,91 to 180,binary,count,18
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,lovastatin,91 to 180,binary,percentage,0.08058017727639
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,rosuvastatin,91 to 180,binary,count,310
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,rosuvastatin,91 to 180,binary,percentage,1.38776971976005
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,alirocumab,91 to 180,binary,count,5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,alirocumab,91 to 180,binary,percentage,0.022383382576775
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,fluvastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,fluvastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,ezetimibe,91 to 180,binary,count,231
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,ezetimibe,91 to 180,binary,percentage,1.03411227504701
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,evolocumab,91 to 180,binary,count,16
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,evolocumab,91 to 180,binary,percentage,0.07162682424568
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,pitavastatin,91 to 180,binary,count,11
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,pitavastatin,91 to 180,binary,percentage,0.049243441668905
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,pravastatin,91 to 180,binary,count,120
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,pravastatin,91 to 180,binary,percentage,0.5372011818426
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,atorvastatin,91 to 180,binary,count,583
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,atorvastatin,91 to 180,binary,percentage,2.60990240845197
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,cerivastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,cerivastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,unexposed,91 to 180,binary,count,21075
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,unexposed,91 to 180,binary,percentage,94.3459575611066
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,lovastatin,181 to 365,binary,count,25
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,lovastatin,181 to 365,binary,percentage,0.111916912883875
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,pitavastatin,181 to 365,binary,count,18
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,pitavastatin,181 to 365,binary,percentage,0.08058017727639
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,ezetimibe,181 to 365,binary,count,260
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,ezetimibe,181 to 365,binary,percentage,1.1639358939923
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,rosuvastatin,181 to 365,binary,count,470
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,rosuvastatin,181 to 365,binary,percentage,2.10403796221685
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,evolocumab,181 to 365,binary,count,26
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,evolocumab,181 to 365,binary,percentage,0.11639358939923
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,alirocumab,181 to 365,binary,count,6
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,alirocumab,181 to 365,binary,percentage,0.02686005909213
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,fluvastatin,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,fluvastatin,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,atorvastatin,181 to 365,binary,count,921
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,atorvastatin,181 to 365,binary,percentage,4.12301907064196
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,pravastatin,181 to 365,binary,count,169
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,pravastatin,181 to 365,binary,percentage,0.756558331094995
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,cerivastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,cerivastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,unexposed,181 to 365,binary,count,20509
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,40 to 59,unexposed,181 to 365,binary,percentage,91.8121586534157
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,number subjects,NA,numeric,count,28264
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,number records,NA,NA,count,28264
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,alirocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,alirocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,fluvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,fluvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,lovastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,lovastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,pitavastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,pitavastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,ezetimibe,0 to 0,binary,count,421
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,ezetimibe,0 to 0,binary,percentage,1.48952731389754
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,rosuvastatin,0 to 0,binary,count,16
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,rosuvastatin,0 to 0,binary,percentage,0.0566091140673648
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,atorvastatin,0 to 0,binary,count,35
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,atorvastatin,0 to 0,binary,percentage,0.123832437022361
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,pravastatin,0 to 0,binary,count,9
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,pravastatin,0 to 0,binary,percentage,0.0318426266628927
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,evolocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,evolocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,cerivastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,cerivastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,unexposed,0 to 0,binary,count,27781
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,unexposed,0 to 0,binary,percentage,98.2911123690914
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,atorvastatin,1 to 30,binary,count,364
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,atorvastatin,1 to 30,binary,percentage,1.28785734503255
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,evolocumab,1 to 30,binary,count,10
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,evolocumab,1 to 30,binary,percentage,0.035380696292103
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,alirocumab,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,alirocumab,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,rosuvastatin,1 to 30,binary,count,161
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,rosuvastatin,1 to 30,binary,percentage,0.569629210302859
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,pravastatin,1 to 30,binary,count,97
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,pravastatin,1 to 30,binary,percentage,0.343192754033399
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,lovastatin,1 to 30,binary,count,26
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,lovastatin,1 to 30,binary,percentage,0.0919898103594679
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,pitavastatin,1 to 30,binary,count,11
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,pitavastatin,1 to 30,binary,percentage,0.0389187659213133
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,ezetimibe,1 to 30,binary,count,193
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,ezetimibe,1 to 30,binary,percentage,0.682847438437588
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,fluvastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,fluvastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,cerivastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,cerivastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,unexposed,1 to 30,binary,count,27419
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,unexposed,1 to 30,binary,percentage,97.0103311633173
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,alirocumab,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,alirocumab,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,atorvastatin,31 to 90,binary,count,598
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,atorvastatin,31 to 90,binary,percentage,2.11576563826776
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,rosuvastatin,31 to 90,binary,count,263
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,rosuvastatin,31 to 90,binary,percentage,0.93051231248231
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,evolocumab,31 to 90,binary,count,21
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,evolocumab,31 to 90,binary,percentage,0.0742994622134164
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,pravastatin,31 to 90,binary,count,155
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,pravastatin,31 to 90,binary,percentage,0.548400792527597
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,pitavastatin,31 to 90,binary,count,11
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,pitavastatin,31 to 90,binary,percentage,0.0389187659213133
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,lovastatin,31 to 90,binary,count,52
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,lovastatin,31 to 90,binary,percentage,0.183979620718936
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,fluvastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,fluvastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,ezetimibe,31 to 90,binary,count,357
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,ezetimibe,31 to 90,binary,percentage,1.26309085762808
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,cerivastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,cerivastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,unexposed,31 to 90,binary,count,26839
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,unexposed,31 to 90,binary,percentage,94.9582507783753
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,lovastatin,91 to 180,binary,count,47
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,lovastatin,91 to 180,binary,percentage,0.166289272572884
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,rosuvastatin,91 to 180,binary,count,454
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,rosuvastatin,91 to 180,binary,percentage,1.60628361166148
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,alirocumab,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,alirocumab,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,fluvastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,fluvastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,ezetimibe,91 to 180,binary,count,419
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,ezetimibe,91 to 180,binary,percentage,1.48245117463912
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,evolocumab,91 to 180,binary,count,36
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,evolocumab,91 to 180,binary,percentage,0.127370506651571
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,pitavastatin,91 to 180,binary,count,22
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,pitavastatin,91 to 180,binary,percentage,0.0778375318426267
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,pravastatin,91 to 180,binary,count,228
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,pravastatin,91 to 180,binary,percentage,0.806679875459949
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,atorvastatin,91 to 180,binary,count,922
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,atorvastatin,91 to 180,binary,percentage,3.2621001981319
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,cerivastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,cerivastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,unexposed,91 to 180,binary,count,26190
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,unexposed,91 to 180,binary,percentage,92.6620435890178
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,lovastatin,181 to 365,binary,count,48
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,lovastatin,181 to 365,binary,percentage,0.169827342202095
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,pitavastatin,181 to 365,binary,count,18
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,pitavastatin,181 to 365,binary,percentage,0.0636852533257855
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,ezetimibe,181 to 365,binary,count,446
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,ezetimibe,181 to 365,binary,percentage,1.57797905462779
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,rosuvastatin,181 to 365,binary,count,687
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,rosuvastatin,181 to 365,binary,percentage,2.43065383526748
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,evolocumab,181 to 365,binary,count,47
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,evolocumab,181 to 365,binary,percentage,0.166289272572884
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,alirocumab,181 to 365,binary,count,6
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,alirocumab,181 to 365,binary,percentage,0.0212284177752618
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,fluvastatin,181 to 365,binary,count,5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,fluvastatin,181 to 365,binary,percentage,0.0176903481460515
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,atorvastatin,181 to 365,binary,count,1385
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,atorvastatin,181 to 365,binary,percentage,4.90022643645627
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,pravastatin,181 to 365,binary,count,279
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,pravastatin,181 to 365,binary,percentage,0.987121426549674
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,cerivastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,cerivastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,unexposed,181 to 365,binary,count,25474
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,60 to 79,unexposed,181 to 365,binary,percentage,90.1287857345033
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,number subjects,NA,numeric,count,6336
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,number records,NA,NA,count,6336
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,alirocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,alirocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,fluvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,fluvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,lovastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,lovastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,pitavastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,pitavastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,ezetimibe,0 to 0,binary,count,111
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,ezetimibe,0 to 0,binary,percentage,1.75189393939394
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,rosuvastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,rosuvastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,atorvastatin,0 to 0,binary,count,16
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,atorvastatin,0 to 0,binary,percentage,0.252525252525253
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,pravastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,pravastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,evolocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,evolocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,cerivastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,cerivastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,unexposed,0 to 0,binary,count,6202
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,unexposed,0 to 0,binary,percentage,97.885101010101
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,atorvastatin,1 to 30,binary,count,111
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,atorvastatin,1 to 30,binary,percentage,1.75189393939394
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,evolocumab,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,evolocumab,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,alirocumab,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,alirocumab,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,rosuvastatin,1 to 30,binary,count,32
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,rosuvastatin,1 to 30,binary,percentage,0.505050505050505
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,pravastatin,1 to 30,binary,count,24
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,pravastatin,1 to 30,binary,percentage,0.378787878787879
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,lovastatin,1 to 30,binary,count,12
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,lovastatin,1 to 30,binary,percentage,0.189393939393939
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,pitavastatin,1 to 30,binary,count,5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,pitavastatin,1 to 30,binary,percentage,0.0789141414141414
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,ezetimibe,1 to 30,binary,count,43
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,ezetimibe,1 to 30,binary,percentage,0.678661616161616
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,fluvastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,fluvastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,cerivastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,cerivastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,unexposed,1 to 30,binary,count,6113
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,unexposed,1 to 30,binary,percentage,96.4804292929293
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,alirocumab,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,alirocumab,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,atorvastatin,31 to 90,binary,count,175
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,atorvastatin,31 to 90,binary,percentage,2.76199494949495
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,rosuvastatin,31 to 90,binary,count,39
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,rosuvastatin,31 to 90,binary,percentage,0.615530303030303
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,evolocumab,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,evolocumab,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,pravastatin,31 to 90,binary,count,41
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,pravastatin,31 to 90,binary,percentage,0.64709595959596
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,pitavastatin,31 to 90,binary,count,5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,pitavastatin,31 to 90,binary,percentage,0.0789141414141414
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,lovastatin,31 to 90,binary,count,21
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,lovastatin,31 to 90,binary,percentage,0.331439393939394
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,fluvastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,fluvastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,ezetimibe,31 to 90,binary,count,68
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,ezetimibe,31 to 90,binary,percentage,1.07323232323232
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,cerivastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,cerivastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,unexposed,31 to 90,binary,count,5989
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,unexposed,31 to 90,binary,percentage,94.5233585858586
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,lovastatin,91 to 180,binary,count,29
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,lovastatin,91 to 180,binary,percentage,0.45770202020202
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,rosuvastatin,91 to 180,binary,count,72
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,rosuvastatin,91 to 180,binary,percentage,1.13636363636364
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,alirocumab,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,alirocumab,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,fluvastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,fluvastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,ezetimibe,91 to 180,binary,count,86
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,ezetimibe,91 to 180,binary,percentage,1.35732323232323
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,evolocumab,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,evolocumab,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,pitavastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,pitavastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,pravastatin,91 to 180,binary,count,49
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,pravastatin,91 to 180,binary,percentage,0.773358585858586
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,atorvastatin,91 to 180,binary,count,242
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,atorvastatin,91 to 180,binary,percentage,3.81944444444444
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,cerivastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,cerivastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,unexposed,91 to 180,binary,count,5861
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,unexposed,91 to 180,binary,percentage,92.5031565656566
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,lovastatin,181 to 365,binary,count,28
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,lovastatin,181 to 365,binary,percentage,0.441919191919192
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,pitavastatin,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,pitavastatin,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,ezetimibe,181 to 365,binary,count,109
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,ezetimibe,181 to 365,binary,percentage,1.72032828282828
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,rosuvastatin,181 to 365,binary,count,110
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,rosuvastatin,181 to 365,binary,percentage,1.73611111111111
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,evolocumab,181 to 365,binary,count,6
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,evolocumab,181 to 365,binary,percentage,0.0946969696969697
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,alirocumab,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,alirocumab,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,fluvastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,fluvastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,atorvastatin,181 to 365,binary,count,343
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,atorvastatin,181 to 365,binary,percentage,5.4135101010101
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,pravastatin,181 to 365,binary,count,52
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,pravastatin,181 to 365,binary,percentage,0.820707070707071
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,cerivastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,cerivastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,unexposed,181 to 365,binary,count,5707
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group,80 to 150,unexposed,181 to 365,binary,percentage,90.072601010101
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,number subjects,NA,numeric,count,135
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,number records,NA,NA,count,135
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,alirocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,alirocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,fluvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,fluvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,lovastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,lovastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,pitavastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,pitavastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,ezetimibe,0 to 0,binary,count,5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,ezetimibe,0 to 0,binary,percentage,3.7037037037037
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,rosuvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,rosuvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,atorvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,atorvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,pravastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,pravastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,evolocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,evolocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,cerivastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,cerivastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,unexposed,0 to 0,binary,count,130
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,unexposed,0 to 0,binary,percentage,96.2962962962963
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,atorvastatin,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,atorvastatin,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,evolocumab,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,evolocumab,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,alirocumab,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,alirocumab,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,rosuvastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,rosuvastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,pravastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,pravastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,lovastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,lovastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,pitavastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,pitavastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,ezetimibe,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,ezetimibe,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,fluvastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,fluvastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,cerivastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,cerivastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,unexposed,1 to 30,binary,count,131
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,unexposed,1 to 30,binary,percentage,97.037037037037
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,alirocumab,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,alirocumab,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,atorvastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,atorvastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,rosuvastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,rosuvastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,evolocumab,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,evolocumab,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,pravastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,pravastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,pitavastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,pitavastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,lovastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,lovastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,fluvastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,fluvastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,ezetimibe,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,ezetimibe,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,cerivastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,cerivastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,unexposed,31 to 90,binary,count,127
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,unexposed,31 to 90,binary,percentage,94.0740740740741
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,lovastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,lovastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,rosuvastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,rosuvastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,alirocumab,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,alirocumab,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,fluvastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,fluvastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,ezetimibe,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,ezetimibe,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,evolocumab,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,evolocumab,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,pitavastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,pitavastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,pravastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,pravastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,atorvastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,atorvastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,cerivastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,cerivastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,unexposed,91 to 180,binary,count,125
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,unexposed,91 to 180,binary,percentage,92.5925925925926
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,lovastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,lovastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,pitavastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,pitavastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,ezetimibe,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,ezetimibe,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,rosuvastatin,181 to 365,binary,count,5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,rosuvastatin,181 to 365,binary,percentage,3.7037037037037
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,evolocumab,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,evolocumab,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,alirocumab,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,alirocumab,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,fluvastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,fluvastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,atorvastatin,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,atorvastatin,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,pravastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,pravastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,cerivastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,cerivastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,unexposed,181 to 365,binary,count,125
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Female,unexposed,181 to 365,binary,percentage,92.5925925925926
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,number subjects,NA,numeric,count,118
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,number records,NA,NA,count,118
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,alirocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,alirocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,fluvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,fluvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,lovastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,lovastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,pitavastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,pitavastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,ezetimibe,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,ezetimibe,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,rosuvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,rosuvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,atorvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,atorvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,pravastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,pravastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,evolocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,evolocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,cerivastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,cerivastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,unexposed,0 to 0,binary,count,115
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,unexposed,0 to 0,binary,percentage,97.4576271186441
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,atorvastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,atorvastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,evolocumab,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,evolocumab,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,alirocumab,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,alirocumab,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,rosuvastatin,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,rosuvastatin,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,pravastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,pravastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,lovastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,lovastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,pitavastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,pitavastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,ezetimibe,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,ezetimibe,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,fluvastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,fluvastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,cerivastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,cerivastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,unexposed,1 to 30,binary,count,115
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,unexposed,1 to 30,binary,percentage,97.4576271186441
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,alirocumab,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,alirocumab,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,atorvastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,atorvastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,rosuvastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,rosuvastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,evolocumab,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,evolocumab,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,pravastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,pravastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,pitavastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,pitavastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,lovastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,lovastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,fluvastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,fluvastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,ezetimibe,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,ezetimibe,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,cerivastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,cerivastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,unexposed,31 to 90,binary,count,111
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,unexposed,31 to 90,binary,percentage,94.0677966101695
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,lovastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,lovastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,rosuvastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,rosuvastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,alirocumab,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,alirocumab,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,fluvastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,fluvastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,ezetimibe,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,ezetimibe,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,evolocumab,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,evolocumab,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,pitavastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,pitavastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,pravastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,pravastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,atorvastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,atorvastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,cerivastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,cerivastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,unexposed,91 to 180,binary,count,113
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,unexposed,91 to 180,binary,percentage,95.7627118644068
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,lovastatin,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,lovastatin,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,pitavastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,pitavastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,ezetimibe,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,ezetimibe,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,rosuvastatin,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,rosuvastatin,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,evolocumab,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,evolocumab,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,alirocumab,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,alirocumab,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,fluvastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,fluvastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,atorvastatin,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,atorvastatin,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,pravastatin,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,pravastatin,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,cerivastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,cerivastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,unexposed,181 to 365,binary,count,112
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,0 to 19 and Male,unexposed,181 to 365,binary,percentage,94.9152542372881
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,number subjects,NA,numeric,count,1135
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,number records,NA,NA,count,1135
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,alirocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,alirocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,fluvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,fluvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,lovastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,lovastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,pitavastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,pitavastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,ezetimibe,0 to 0,binary,count,14
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,ezetimibe,0 to 0,binary,percentage,1.23348017621145
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,rosuvastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,rosuvastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,atorvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,atorvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,pravastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,pravastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,evolocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,evolocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,cerivastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,cerivastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,unexposed,0 to 0,binary,count,1120
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,unexposed,0 to 0,binary,percentage,98.6784140969163
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,atorvastatin,1 to 30,binary,count,12
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,atorvastatin,1 to 30,binary,percentage,1.05726872246696
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,evolocumab,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,evolocumab,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,alirocumab,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,alirocumab,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,rosuvastatin,1 to 30,binary,count,5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,rosuvastatin,1 to 30,binary,percentage,0.440528634361233
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,pravastatin,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,pravastatin,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,lovastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,lovastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,pitavastatin,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,pitavastatin,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,ezetimibe,1 to 30,binary,count,8
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,ezetimibe,1 to 30,binary,percentage,0.704845814977974
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,fluvastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,fluvastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,cerivastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,cerivastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,unexposed,1 to 30,binary,count,1108
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,unexposed,1 to 30,binary,percentage,97.6211453744493
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,alirocumab,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,alirocumab,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,atorvastatin,31 to 90,binary,count,17
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,atorvastatin,31 to 90,binary,percentage,1.49779735682819
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,rosuvastatin,31 to 90,binary,count,7
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,rosuvastatin,31 to 90,binary,percentage,0.616740088105727
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,evolocumab,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,evolocumab,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,pravastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,pravastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,pitavastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,pitavastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,lovastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,lovastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,fluvastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,fluvastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,ezetimibe,31 to 90,binary,count,9
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,ezetimibe,31 to 90,binary,percentage,0.79295154185022
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,cerivastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,cerivastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,unexposed,31 to 90,binary,count,1096
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,unexposed,31 to 90,binary,percentage,96.5638766519824
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,lovastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,lovastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,rosuvastatin,91 to 180,binary,count,10
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,rosuvastatin,91 to 180,binary,percentage,0.881057268722467
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,alirocumab,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,alirocumab,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,fluvastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,fluvastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,ezetimibe,91 to 180,binary,count,11
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,ezetimibe,91 to 180,binary,percentage,0.969162995594714
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,evolocumab,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,evolocumab,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,pitavastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,pitavastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,pravastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,pravastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,atorvastatin,91 to 180,binary,count,24
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,atorvastatin,91 to 180,binary,percentage,2.11453744493392
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,cerivastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,cerivastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,unexposed,91 to 180,binary,count,1083
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,unexposed,91 to 180,binary,percentage,95.4185022026432
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,lovastatin,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,lovastatin,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,pitavastatin,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,pitavastatin,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,ezetimibe,181 to 365,binary,count,11
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,ezetimibe,181 to 365,binary,percentage,0.969162995594714
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,rosuvastatin,181 to 365,binary,count,16
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,rosuvastatin,181 to 365,binary,percentage,1.40969162995595
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,evolocumab,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,evolocumab,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,alirocumab,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,alirocumab,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,fluvastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,fluvastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,atorvastatin,181 to 365,binary,count,31
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,atorvastatin,181 to 365,binary,percentage,2.73127753303965
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,pravastatin,181 to 365,binary,count,10
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,pravastatin,181 to 365,binary,percentage,0.881057268722467
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,cerivastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,cerivastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,unexposed,181 to 365,binary,count,1066
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Female,unexposed,181 to 365,binary,percentage,93.920704845815
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,number subjects,NA,numeric,count,1706
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,number records,NA,NA,count,1706
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,alirocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,alirocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,fluvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,fluvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,lovastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,lovastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,pitavastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,pitavastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,ezetimibe,0 to 0,binary,count,28
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,ezetimibe,0 to 0,binary,percentage,1.64126611957796
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,rosuvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,rosuvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,atorvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,atorvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,pravastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,pravastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,evolocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,evolocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,cerivastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,cerivastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,unexposed,0 to 0,binary,count,1678
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,unexposed,0 to 0,binary,percentage,98.358733880422
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,atorvastatin,1 to 30,binary,count,13
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,atorvastatin,1 to 30,binary,percentage,0.762016412661196
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,evolocumab,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,evolocumab,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,alirocumab,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,alirocumab,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,rosuvastatin,1 to 30,binary,count,6
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,rosuvastatin,1 to 30,binary,percentage,0.351699882766706
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,pravastatin,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,pravastatin,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,lovastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,lovastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,pitavastatin,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,pitavastatin,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,ezetimibe,1 to 30,binary,count,11
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,ezetimibe,1 to 30,binary,percentage,0.644783118405627
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,fluvastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,fluvastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,cerivastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,cerivastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,unexposed,1 to 30,binary,count,1673
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,unexposed,1 to 30,binary,percentage,98.0656506447831
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,alirocumab,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,alirocumab,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,atorvastatin,31 to 90,binary,count,16
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,atorvastatin,31 to 90,binary,percentage,0.937866354044549
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,rosuvastatin,31 to 90,binary,count,6
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,rosuvastatin,31 to 90,binary,percentage,0.351699882766706
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,evolocumab,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,evolocumab,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,pravastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,pravastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,pitavastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,pitavastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,lovastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,lovastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,fluvastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,fluvastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,ezetimibe,31 to 90,binary,count,22
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,ezetimibe,31 to 90,binary,percentage,1.28956623681125
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,cerivastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,cerivastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,unexposed,31 to 90,binary,count,1656
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,unexposed,31 to 90,binary,percentage,97.0691676436108
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,lovastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,lovastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,rosuvastatin,91 to 180,binary,count,15
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,rosuvastatin,91 to 180,binary,percentage,0.879249706916764
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,alirocumab,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,alirocumab,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,fluvastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,fluvastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,ezetimibe,91 to 180,binary,count,21
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,ezetimibe,91 to 180,binary,percentage,1.23094958968347
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,evolocumab,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,evolocumab,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,pitavastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,pitavastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,pravastatin,91 to 180,binary,count,8
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,pravastatin,91 to 180,binary,percentage,0.468933177022274
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,atorvastatin,91 to 180,binary,count,26
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,atorvastatin,91 to 180,binary,percentage,1.52403282532239
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,cerivastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,cerivastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,unexposed,91 to 180,binary,count,1634
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,unexposed,91 to 180,binary,percentage,95.7796014067995
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,lovastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,lovastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,pitavastatin,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,pitavastatin,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,ezetimibe,181 to 365,binary,count,15
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,ezetimibe,181 to 365,binary,percentage,0.879249706916764
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,rosuvastatin,181 to 365,binary,count,32
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,rosuvastatin,181 to 365,binary,percentage,1.8757327080891
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,evolocumab,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,evolocumab,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,alirocumab,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,alirocumab,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,fluvastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,fluvastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,atorvastatin,181 to 365,binary,count,56
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,atorvastatin,181 to 365,binary,percentage,3.28253223915592
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,pravastatin,181 to 365,binary,count,12
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,pravastatin,181 to 365,binary,percentage,0.703399765533411
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,cerivastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,cerivastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,unexposed,181 to 365,binary,count,1591
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,20 to 39 and Male,unexposed,181 to 365,binary,percentage,93.2590855803048
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,number subjects,NA,numeric,count,10387
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,number records,NA,NA,count,10387
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,alirocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,alirocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,fluvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,fluvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,lovastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,lovastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,pitavastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,pitavastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,ezetimibe,0 to 0,binary,count,104
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,ezetimibe,0 to 0,binary,percentage,1.00125156445557
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,rosuvastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,rosuvastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,atorvastatin,0 to 0,binary,count,15
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,atorvastatin,0 to 0,binary,percentage,0.144411283334938
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,pravastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,pravastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,evolocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,evolocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,cerivastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,cerivastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,unexposed,0 to 0,binary,count,10263
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,unexposed,0 to 0,binary,percentage,98.8062000577645
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,atorvastatin,1 to 30,binary,count,88
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,atorvastatin,1 to 30,binary,percentage,0.847212862231636
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,evolocumab,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,evolocumab,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,alirocumab,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,alirocumab,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,rosuvastatin,1 to 30,binary,count,51
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,rosuvastatin,1 to 30,binary,percentage,0.490998363338789
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,pravastatin,1 to 30,binary,count,40
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,pravastatin,1 to 30,binary,percentage,0.385096755559834
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,lovastatin,1 to 30,binary,count,5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,lovastatin,1 to 30,binary,percentage,0.0481370944449793
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,pitavastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,pitavastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,ezetimibe,1 to 30,binary,count,63
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,ezetimibe,1 to 30,binary,percentage,0.606527390006739
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,fluvastatin,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,fluvastatin,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,cerivastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,cerivastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,unexposed,1 to 30,binary,count,10142
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,unexposed,1 to 30,binary,percentage,97.641282372196
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,alirocumab,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,alirocumab,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,atorvastatin,31 to 90,binary,count,185
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,atorvastatin,31 to 90,binary,percentage,1.78107249446423
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,rosuvastatin,31 to 90,binary,count,90
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,rosuvastatin,31 to 90,binary,percentage,0.866467700009627
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,evolocumab,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,evolocumab,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,pravastatin,31 to 90,binary,count,54
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,pravastatin,31 to 90,binary,percentage,0.519880620005777
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,pitavastatin,31 to 90,binary,count,7
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,pitavastatin,31 to 90,binary,percentage,0.067391932222971
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,lovastatin,31 to 90,binary,count,9
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,lovastatin,31 to 90,binary,percentage,0.0866467700009627
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,fluvastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,fluvastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,ezetimibe,31 to 90,binary,count,93
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,ezetimibe,31 to 90,binary,percentage,0.895349956676615
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,cerivastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,cerivastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,unexposed,31 to 90,binary,count,9955
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,unexposed,31 to 90,binary,percentage,95.8409550399538
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,lovastatin,91 to 180,binary,count,8
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,lovastatin,91 to 180,binary,percentage,0.0770193511119669
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,rosuvastatin,91 to 180,binary,count,131
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,rosuvastatin,91 to 180,binary,percentage,1.26119187445846
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,alirocumab,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,alirocumab,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,fluvastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,fluvastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,ezetimibe,91 to 180,binary,count,106
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,ezetimibe,91 to 180,binary,percentage,1.02050640223356
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,evolocumab,91 to 180,binary,count,10
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,evolocumab,91 to 180,binary,percentage,0.0962741888899586
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,pitavastatin,91 to 180,binary,count,7
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,pitavastatin,91 to 180,binary,percentage,0.067391932222971
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,pravastatin,91 to 180,binary,count,74
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,pravastatin,91 to 180,binary,percentage,0.712428997785694
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,atorvastatin,91 to 180,binary,count,264
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,atorvastatin,91 to 180,binary,percentage,2.54163858669491
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,cerivastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,cerivastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,unexposed,91 to 180,binary,count,9799
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,unexposed,91 to 180,binary,percentage,94.3390776932704
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,lovastatin,181 to 365,binary,count,15
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,lovastatin,181 to 365,binary,percentage,0.144411283334938
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,pitavastatin,181 to 365,binary,count,12
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,pitavastatin,181 to 365,binary,percentage,0.11552902666795
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,ezetimibe,181 to 365,binary,count,119
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,ezetimibe,181 to 365,binary,percentage,1.14566284779051
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,rosuvastatin,181 to 365,binary,count,206
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,rosuvastatin,181 to 365,binary,percentage,1.98324829113315
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,evolocumab,181 to 365,binary,count,14
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,evolocumab,181 to 365,binary,percentage,0.134783864445942
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,alirocumab,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,alirocumab,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,fluvastatin,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,fluvastatin,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,atorvastatin,181 to 365,binary,count,412
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,atorvastatin,181 to 365,binary,percentage,3.96649658226629
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,pravastatin,181 to 365,binary,count,104
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,pravastatin,181 to 365,binary,percentage,1.00125156445557
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,cerivastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,cerivastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,unexposed,181 to 365,binary,count,9540
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Female,unexposed,181 to 365,binary,percentage,91.8455762010205
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,number subjects,NA,numeric,count,11951
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,number records,NA,NA,count,11951
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,alirocumab,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,alirocumab,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,fluvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,fluvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,lovastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,lovastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,pitavastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,pitavastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,ezetimibe,0 to 0,binary,count,138
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,ezetimibe,0 to 0,binary,percentage,1.15471508660363
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,rosuvastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,rosuvastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,atorvastatin,0 to 0,binary,count,18
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,atorvastatin,0 to 0,binary,percentage,0.150615011296126
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,pravastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,pravastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,evolocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,evolocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,cerivastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,cerivastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,unexposed,0 to 0,binary,count,11786
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,unexposed,0 to 0,binary,percentage,98.6193623964522
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,atorvastatin,1 to 30,binary,count,141
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,atorvastatin,1 to 30,binary,percentage,1.17981758848632
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,evolocumab,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,evolocumab,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,alirocumab,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,alirocumab,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,rosuvastatin,1 to 30,binary,count,85
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,rosuvastatin,1 to 30,binary,percentage,0.711237553342816
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,pravastatin,1 to 30,binary,count,18
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,pravastatin,1 to 30,binary,percentage,0.150615011296126
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,lovastatin,1 to 30,binary,count,5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,lovastatin,1 to 30,binary,percentage,0.0418375031378127
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,pitavastatin,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,pitavastatin,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,ezetimibe,1 to 30,binary,count,73
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,ezetimibe,1 to 30,binary,percentage,0.610827545812066
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,fluvastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,fluvastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,cerivastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,cerivastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,unexposed,1 to 30,binary,count,11628
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,unexposed,1 to 30,binary,percentage,97.2972972972973
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,alirocumab,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,alirocumab,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,atorvastatin,31 to 90,binary,count,224
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,atorvastatin,31 to 90,binary,percentage,1.87432014057401
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,rosuvastatin,31 to 90,binary,count,104
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,rosuvastatin,31 to 90,binary,percentage,0.870220065266505
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,evolocumab,31 to 90,binary,count,5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,evolocumab,31 to 90,binary,percentage,0.0418375031378127
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,pravastatin,31 to 90,binary,count,35
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,pravastatin,31 to 90,binary,percentage,0.292862521964689
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,pitavastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,pitavastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,lovastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,lovastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,fluvastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,fluvastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,ezetimibe,31 to 90,binary,count,115
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,ezetimibe,31 to 90,binary,percentage,0.962262572169693
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,cerivastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,cerivastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,unexposed,31 to 90,binary,count,11468
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,unexposed,31 to 90,binary,percentage,95.9584971968873
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,lovastatin,91 to 180,binary,count,10
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,lovastatin,91 to 180,binary,percentage,0.0836750062756255
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,rosuvastatin,91 to 180,binary,count,179
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,rosuvastatin,91 to 180,binary,percentage,1.4977826123337
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,alirocumab,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,alirocumab,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,fluvastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,fluvastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,ezetimibe,91 to 180,binary,count,125
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,ezetimibe,91 to 180,binary,percentage,1.04593757844532
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,evolocumab,91 to 180,binary,count,6
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,evolocumab,91 to 180,binary,percentage,0.0502050037653753
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,pitavastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,pitavastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,pravastatin,91 to 180,binary,count,46
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,pravastatin,91 to 180,binary,percentage,0.384905028867877
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,atorvastatin,91 to 180,binary,count,319
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,atorvastatin,91 to 180,binary,percentage,2.66923270019245
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,cerivastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,cerivastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,unexposed,91 to 180,binary,count,11276
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,unexposed,91 to 180,binary,percentage,94.3519370763953
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,lovastatin,181 to 365,binary,count,10
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,lovastatin,181 to 365,binary,percentage,0.0836750062756255
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,pitavastatin,181 to 365,binary,count,6
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,pitavastatin,181 to 365,binary,percentage,0.0502050037653753
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,ezetimibe,181 to 365,binary,count,141
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,ezetimibe,181 to 365,binary,percentage,1.17981758848632
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,rosuvastatin,181 to 365,binary,count,264
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,rosuvastatin,181 to 365,binary,percentage,2.20902016567651
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,evolocumab,181 to 365,binary,count,12
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,evolocumab,181 to 365,binary,percentage,0.100410007530751
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,alirocumab,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,alirocumab,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,fluvastatin,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,fluvastatin,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,atorvastatin,181 to 365,binary,count,509
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,atorvastatin,181 to 365,binary,percentage,4.25905781942934
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,pravastatin,181 to 365,binary,count,65
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,pravastatin,181 to 365,binary,percentage,0.543887540791566
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,cerivastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,cerivastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,unexposed,181 to 365,binary,count,10969
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,40 to 59 and Male,unexposed,181 to 365,binary,percentage,91.7831143837336
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,number subjects,NA,numeric,count,15191
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,number records,NA,NA,count,15191
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,alirocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,alirocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,fluvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,fluvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,lovastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,lovastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,pitavastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,pitavastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,ezetimibe,0 to 0,binary,count,197
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,ezetimibe,0 to 0,binary,percentage,1.29682048581397
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,rosuvastatin,0 to 0,binary,count,9
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,rosuvastatin,0 to 0,binary,percentage,0.059245605950892
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,atorvastatin,0 to 0,binary,count,17
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,atorvastatin,0 to 0,binary,percentage,0.111908366796129
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,pravastatin,0 to 0,binary,count,6
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,pravastatin,0 to 0,binary,percentage,0.039497070633928
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,evolocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,evolocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,cerivastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,cerivastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,unexposed,0 to 0,binary,count,14963
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,unexposed,0 to 0,binary,percentage,98.4991113159107
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,atorvastatin,1 to 30,binary,count,173
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,atorvastatin,1 to 30,binary,percentage,1.13883220327826
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,evolocumab,1 to 30,binary,count,5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,evolocumab,1 to 30,binary,percentage,0.0329142255282733
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,alirocumab,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,alirocumab,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,rosuvastatin,1 to 30,binary,count,69
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,rosuvastatin,1 to 30,binary,percentage,0.454216312290172
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,pravastatin,1 to 30,binary,count,57
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,pravastatin,1 to 30,binary,percentage,0.375222171022316
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,lovastatin,1 to 30,binary,count,21
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,lovastatin,1 to 30,binary,percentage,0.138239747218748
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,pitavastatin,1 to 30,binary,count,8
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,pitavastatin,1 to 30,binary,percentage,0.0526627608452373
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,ezetimibe,1 to 30,binary,count,110
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,ezetimibe,1 to 30,binary,percentage,0.724112961622013
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,fluvastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,fluvastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,cerivastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,cerivastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,unexposed,1 to 30,binary,count,14757
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,unexposed,1 to 30,binary,percentage,97.1430452241459
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,alirocumab,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,alirocumab,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,atorvastatin,31 to 90,binary,count,310
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,atorvastatin,31 to 90,binary,percentage,2.04068198275295
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,rosuvastatin,31 to 90,binary,count,128
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,rosuvastatin,31 to 90,binary,percentage,0.842604173523797
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,evolocumab,31 to 90,binary,count,8
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,evolocumab,31 to 90,binary,percentage,0.0526627608452373
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,pravastatin,31 to 90,binary,count,90
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,pravastatin,31 to 90,binary,percentage,0.59245605950892
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,pitavastatin,31 to 90,binary,count,8
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,pitavastatin,31 to 90,binary,percentage,0.0526627608452373
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,lovastatin,31 to 90,binary,count,33
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,lovastatin,31 to 90,binary,percentage,0.217233888486604
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,fluvastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,fluvastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,ezetimibe,31 to 90,binary,count,180
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,ezetimibe,31 to 90,binary,percentage,1.18491211901784
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,cerivastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,cerivastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,unexposed,31 to 90,binary,count,14449
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,unexposed,31 to 90,binary,percentage,95.1155289316042
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,lovastatin,91 to 180,binary,count,30
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,lovastatin,91 to 180,binary,percentage,0.19748535316964
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,rosuvastatin,91 to 180,binary,count,234
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,rosuvastatin,91 to 180,binary,percentage,1.54038575472319
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,alirocumab,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,alirocumab,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,fluvastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,fluvastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,ezetimibe,91 to 180,binary,count,218
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,ezetimibe,91 to 180,binary,percentage,1.43506023303272
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,evolocumab,91 to 180,binary,count,15
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,evolocumab,91 to 180,binary,percentage,0.09874267658482
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,pitavastatin,91 to 180,binary,count,13
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,pitavastatin,91 to 180,binary,percentage,0.0855769863735106
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,pravastatin,91 to 180,binary,count,144
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,pravastatin,91 to 180,binary,percentage,0.947929695214272
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,atorvastatin,91 to 180,binary,count,481
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,atorvastatin,91 to 180,binary,percentage,3.16634849581989
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,cerivastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,cerivastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,unexposed,91 to 180,binary,count,14085
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,unexposed,91 to 180,binary,percentage,92.7193733131459
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,lovastatin,181 to 365,binary,count,35
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,lovastatin,181 to 365,binary,percentage,0.230399578697913
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,pitavastatin,181 to 365,binary,count,9
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,pitavastatin,181 to 365,binary,percentage,0.059245605950892
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,ezetimibe,181 to 365,binary,count,223
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,ezetimibe,181 to 365,binary,percentage,1.46797445856099
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,rosuvastatin,181 to 365,binary,count,353
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,rosuvastatin,181 to 365,binary,percentage,2.3237443222961
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,evolocumab,181 to 365,binary,count,23
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,evolocumab,181 to 365,binary,percentage,0.151405437430057
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,alirocumab,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,alirocumab,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,fluvastatin,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,fluvastatin,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,atorvastatin,181 to 365,binary,count,698
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,atorvastatin,181 to 365,binary,percentage,4.59482588374696
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,pravastatin,181 to 365,binary,count,167
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,pravastatin,181 to 365,binary,percentage,1.09933513264433
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,cerivastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,cerivastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,unexposed,181 to 365,binary,count,13744
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Female,unexposed,181 to 365,binary,percentage,90.4746231321177
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,number subjects,NA,numeric,count,13073
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,number records,NA,NA,count,13073
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,alirocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,alirocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,fluvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,fluvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,lovastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,lovastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,pitavastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,pitavastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,ezetimibe,0 to 0,binary,count,224
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,ezetimibe,0 to 0,binary,percentage,1.7134552130345
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,rosuvastatin,0 to 0,binary,count,7
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,rosuvastatin,0 to 0,binary,percentage,0.0535454754073281
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,atorvastatin,0 to 0,binary,count,18
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,atorvastatin,0 to 0,binary,percentage,0.137688365333129
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,pravastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,pravastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,evolocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,evolocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,cerivastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,cerivastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,unexposed,0 to 0,binary,count,12818
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,unexposed,0 to 0,binary,percentage,98.0494148244473
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,atorvastatin,1 to 30,binary,count,191
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,atorvastatin,1 to 30,binary,percentage,1.46102654325709
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,evolocumab,1 to 30,binary,count,5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,evolocumab,1 to 30,binary,percentage,0.0382467681480915
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,alirocumab,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,alirocumab,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,rosuvastatin,1 to 30,binary,count,92
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,rosuvastatin,1 to 30,binary,percentage,0.703740533924883
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,pravastatin,1 to 30,binary,count,40
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,pravastatin,1 to 30,binary,percentage,0.305974145184732
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,lovastatin,1 to 30,binary,count,5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,lovastatin,1 to 30,binary,percentage,0.0382467681480915
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,pitavastatin,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,pitavastatin,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,ezetimibe,1 to 30,binary,count,83
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,ezetimibe,1 to 30,binary,percentage,0.634896351258319
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,fluvastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,fluvastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,cerivastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,cerivastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,unexposed,1 to 30,binary,count,12662
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,unexposed,1 to 30,binary,percentage,96.8561156582269
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,alirocumab,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,alirocumab,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,atorvastatin,31 to 90,binary,count,288
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,atorvastatin,31 to 90,binary,percentage,2.20301384533007
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,rosuvastatin,31 to 90,binary,count,135
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,rosuvastatin,31 to 90,binary,percentage,1.03266273999847
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,evolocumab,31 to 90,binary,count,13
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,evolocumab,31 to 90,binary,percentage,0.0994415971850379
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,pravastatin,31 to 90,binary,count,65
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,pravastatin,31 to 90,binary,percentage,0.497207985925189
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,pitavastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,pitavastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,lovastatin,31 to 90,binary,count,19
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,lovastatin,31 to 90,binary,percentage,0.145337718962748
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,fluvastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,fluvastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,ezetimibe,31 to 90,binary,count,177
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,ezetimibe,31 to 90,binary,percentage,1.35393559244244
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,cerivastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,cerivastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,unexposed,31 to 90,binary,count,12390
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,unexposed,31 to 90,binary,percentage,94.7754914709707
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,lovastatin,91 to 180,binary,count,17
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,lovastatin,91 to 180,binary,percentage,0.130039011703511
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,rosuvastatin,91 to 180,binary,count,220
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,rosuvastatin,91 to 180,binary,percentage,1.68285779851603
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,alirocumab,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,alirocumab,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,fluvastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,fluvastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,ezetimibe,91 to 180,binary,count,201
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,ezetimibe,91 to 180,binary,percentage,1.53752007955328
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,evolocumab,91 to 180,binary,count,21
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,evolocumab,91 to 180,binary,percentage,0.160636426221984
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,pitavastatin,91 to 180,binary,count,9
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,pitavastatin,91 to 180,binary,percentage,0.0688441826665647
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,pravastatin,91 to 180,binary,count,84
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,pravastatin,91 to 180,binary,percentage,0.642545704887937
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,atorvastatin,91 to 180,binary,count,441
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,atorvastatin,91 to 180,binary,percentage,3.37336495066167
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,cerivastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,cerivastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,unexposed,91 to 180,binary,count,12105
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,unexposed,91 to 180,binary,percentage,92.5954256865295
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,lovastatin,181 to 365,binary,count,13
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,lovastatin,181 to 365,binary,percentage,0.0994415971850379
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,pitavastatin,181 to 365,binary,count,9
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,pitavastatin,181 to 365,binary,percentage,0.0688441826665647
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,ezetimibe,181 to 365,binary,count,223
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,ezetimibe,181 to 365,binary,percentage,1.70580585940488
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,rosuvastatin,181 to 365,binary,count,334
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,rosuvastatin,181 to 365,binary,percentage,2.55488411229251
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,evolocumab,181 to 365,binary,count,24
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,evolocumab,181 to 365,binary,percentage,0.183584487110839
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,alirocumab,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,alirocumab,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,fluvastatin,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,fluvastatin,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,atorvastatin,181 to 365,binary,count,687
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,atorvastatin,181 to 365,binary,percentage,5.25510594354777
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,pravastatin,181 to 365,binary,count,112
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,pravastatin,181 to 365,binary,percentage,0.856727606517249
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,cerivastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,cerivastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,unexposed,181 to 365,binary,count,11730
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,60 to 79 and Male,unexposed,181 to 365,binary,percentage,89.7269180754226
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,number subjects,NA,numeric,count,3691
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,number records,NA,NA,count,3691
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,alirocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,alirocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,fluvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,fluvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,lovastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,lovastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,pitavastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,pitavastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,ezetimibe,0 to 0,binary,count,64
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,ezetimibe,0 to 0,binary,percentage,1.73394743971823
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,rosuvastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,rosuvastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,atorvastatin,0 to 0,binary,count,7
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,atorvastatin,0 to 0,binary,percentage,0.189650501219182
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,pravastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,pravastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,evolocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,evolocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,cerivastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,cerivastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,unexposed,0 to 0,binary,count,3616
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,unexposed,0 to 0,binary,percentage,97.9680303440802
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,atorvastatin,1 to 30,binary,count,69
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,atorvastatin,1 to 30,binary,percentage,1.86941208344622
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,evolocumab,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,evolocumab,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,alirocumab,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,alirocumab,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,rosuvastatin,1 to 30,binary,count,17
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,rosuvastatin,1 to 30,binary,percentage,0.460579788675156
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,pravastatin,1 to 30,binary,count,15
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,pravastatin,1 to 30,binary,percentage,0.406393931183961
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,lovastatin,1 to 30,binary,count,9
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,lovastatin,1 to 30,binary,percentage,0.243836358710377
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,pitavastatin,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,pitavastatin,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,ezetimibe,1 to 30,binary,count,26
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,ezetimibe,1 to 30,binary,percentage,0.704416147385532
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,fluvastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,fluvastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,cerivastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,cerivastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,unexposed,1 to 30,binary,count,3554
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,unexposed,1 to 30,binary,percentage,96.2882687618532
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,alirocumab,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,alirocumab,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,atorvastatin,31 to 90,binary,count,96
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,atorvastatin,31 to 90,binary,percentage,2.60092115957735
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,rosuvastatin,31 to 90,binary,count,25
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,rosuvastatin,31 to 90,binary,percentage,0.677323218639935
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,evolocumab,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,evolocumab,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,pravastatin,31 to 90,binary,count,24
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,pravastatin,31 to 90,binary,percentage,0.650230289894338
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,pitavastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,pitavastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,lovastatin,31 to 90,binary,count,13
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,lovastatin,31 to 90,binary,percentage,0.352208073692766
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,fluvastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,fluvastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,ezetimibe,31 to 90,binary,count,38
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,ezetimibe,31 to 90,binary,percentage,1.0295312923327
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,cerivastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,cerivastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,unexposed,31 to 90,binary,count,3494
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,unexposed,31 to 90,binary,percentage,94.6626930371173
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,lovastatin,91 to 180,binary,count,19
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,lovastatin,91 to 180,binary,percentage,0.514765646166351
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,rosuvastatin,91 to 180,binary,count,37
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,rosuvastatin,91 to 180,binary,percentage,1.0024383635871
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,alirocumab,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,alirocumab,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,fluvastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,fluvastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,ezetimibe,91 to 180,binary,count,60
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,ezetimibe,91 to 180,binary,percentage,1.62557572473584
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,evolocumab,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,evolocumab,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,pitavastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,pitavastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,pravastatin,91 to 180,binary,count,33
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,pravastatin,91 to 180,binary,percentage,0.894066648604714
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,atorvastatin,91 to 180,binary,count,150
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,atorvastatin,91 to 180,binary,percentage,4.06393931183961
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,cerivastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,cerivastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,unexposed,91 to 180,binary,count,3395
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,unexposed,91 to 180,binary,percentage,91.9804930913032
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,lovastatin,181 to 365,binary,count,21
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,lovastatin,181 to 365,binary,percentage,0.568951503657545
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,pitavastatin,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,pitavastatin,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,ezetimibe,181 to 365,binary,count,69
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,ezetimibe,181 to 365,binary,percentage,1.86941208344622
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,rosuvastatin,181 to 365,binary,count,56
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,rosuvastatin,181 to 365,binary,percentage,1.51720400975345
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,evolocumab,181 to 365,binary,count,5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,evolocumab,181 to 365,binary,percentage,0.135464643727987
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,alirocumab,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,alirocumab,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,fluvastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,fluvastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,atorvastatin,181 to 365,binary,count,205
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,atorvastatin,181 to 365,binary,percentage,5.55405039284747
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,pravastatin,181 to 365,binary,count,33
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,pravastatin,181 to 365,binary,percentage,0.894066648604714
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,cerivastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,cerivastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,unexposed,181 to 365,binary,count,3314
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Female,unexposed,181 to 365,binary,percentage,89.7859658629098
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,number subjects,NA,numeric,count,2645
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,number records,NA,NA,count,2645
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,alirocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,alirocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,fluvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,fluvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,lovastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,lovastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,pitavastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,pitavastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,ezetimibe,0 to 0,binary,count,47
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,ezetimibe,0 to 0,binary,percentage,1.77693761814745
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,rosuvastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,rosuvastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,atorvastatin,0 to 0,binary,count,9
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,atorvastatin,0 to 0,binary,percentage,0.340264650283554
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,pravastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,pravastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,evolocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,evolocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,cerivastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,cerivastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,unexposed,0 to 0,binary,count,2586
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,unexposed,0 to 0,binary,percentage,97.7693761814745
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,atorvastatin,1 to 30,binary,count,42
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,atorvastatin,1 to 30,binary,percentage,1.58790170132325
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,evolocumab,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,evolocumab,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,alirocumab,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,alirocumab,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,rosuvastatin,1 to 30,binary,count,15
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,rosuvastatin,1 to 30,binary,percentage,0.56710775047259
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,pravastatin,1 to 30,binary,count,9
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,pravastatin,1 to 30,binary,percentage,0.340264650283554
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,lovastatin,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,lovastatin,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,pitavastatin,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,pitavastatin,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,ezetimibe,1 to 30,binary,count,17
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,ezetimibe,1 to 30,binary,percentage,0.642722117202268
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,fluvastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,fluvastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,cerivastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,cerivastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,unexposed,1 to 30,binary,count,2559
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,unexposed,1 to 30,binary,percentage,96.7485822306238
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,alirocumab,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,alirocumab,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,atorvastatin,31 to 90,binary,count,79
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,atorvastatin,31 to 90,binary,percentage,2.98676748582231
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,rosuvastatin,31 to 90,binary,count,14
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,rosuvastatin,31 to 90,binary,percentage,0.52930056710775
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,evolocumab,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,evolocumab,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,pravastatin,31 to 90,binary,count,17
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,pravastatin,31 to 90,binary,percentage,0.642722117202268
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,pitavastatin,31 to 90,binary,count,5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,pitavastatin,31 to 90,binary,percentage,0.189035916824197
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,lovastatin,31 to 90,binary,count,8
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,lovastatin,31 to 90,binary,percentage,0.302457466918715
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,fluvastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,fluvastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,ezetimibe,31 to 90,binary,count,30
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,ezetimibe,31 to 90,binary,percentage,1.13421550094518
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,cerivastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,cerivastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,unexposed,31 to 90,binary,count,2495
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,unexposed,31 to 90,binary,percentage,94.3289224952741
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,lovastatin,91 to 180,binary,count,10
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,lovastatin,91 to 180,binary,percentage,0.378071833648393
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,rosuvastatin,91 to 180,binary,count,35
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,rosuvastatin,91 to 180,binary,percentage,1.32325141776938
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,alirocumab,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,alirocumab,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,fluvastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,fluvastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,ezetimibe,91 to 180,binary,count,26
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,ezetimibe,91 to 180,binary,percentage,0.982986767485822
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,evolocumab,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,evolocumab,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,pitavastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,pitavastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,pravastatin,91 to 180,binary,count,16
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,pravastatin,91 to 180,binary,percentage,0.604914933837429
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,atorvastatin,91 to 180,binary,count,92
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,atorvastatin,91 to 180,binary,percentage,3.47826086956522
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,cerivastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,cerivastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,unexposed,91 to 180,binary,count,2466
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,unexposed,91 to 180,binary,percentage,93.2325141776938
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,lovastatin,181 to 365,binary,count,7
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,lovastatin,181 to 365,binary,percentage,0.264650283553875
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,pitavastatin,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,pitavastatin,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,ezetimibe,181 to 365,binary,count,40
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,ezetimibe,181 to 365,binary,percentage,1.51228733459357
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,rosuvastatin,181 to 365,binary,count,54
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,rosuvastatin,181 to 365,binary,percentage,2.04158790170132
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,evolocumab,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,evolocumab,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,alirocumab,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,alirocumab,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,fluvastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,fluvastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,atorvastatin,181 to 365,binary,count,138
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,atorvastatin,181 to 365,binary,percentage,5.21739130434783
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,pravastatin,181 to 365,binary,count,19
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,pravastatin,181 to 365,binary,percentage,0.718336483931947
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,cerivastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,cerivastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,unexposed,181 to 365,binary,count,2393
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,age_group and sex,80 to 150 and Male,unexposed,181 to 365,binary,percentage,90.4725897920605
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,number subjects,NA,numeric,count,30539
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,number records,NA,NA,count,30539
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,alirocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,alirocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,fluvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,fluvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,lovastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,lovastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,pitavastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,pitavastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,ezetimibe,0 to 0,binary,count,384
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,ezetimibe,0 to 0,binary,percentage,1.25740855954681
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,rosuvastatin,0 to 0,binary,count,14
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,rosuvastatin,0 to 0,binary,percentage,0.0458430204001441
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,atorvastatin,0 to 0,binary,count,39
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,atorvastatin,0 to 0,binary,percentage,0.127705556828973
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,pravastatin,0 to 0,binary,count,11
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,pravastatin,0 to 0,binary,percentage,0.0360195160286846
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,evolocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,evolocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,cerivastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,cerivastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,unexposed,0 to 0,binary,count,30092
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,unexposed,0 to 0,binary,percentage,98.5362978486525
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,atorvastatin,1 to 30,binary,count,345
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,atorvastatin,1 to 30,binary,percentage,1.12970300271784
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,evolocumab,1 to 30,binary,count,9
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,evolocumab,1 to 30,binary,percentage,0.0294705131143783
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,alirocumab,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,alirocumab,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,rosuvastatin,1 to 30,binary,count,142
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,rosuvastatin,1 to 30,binary,percentage,0.464979206915747
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,pravastatin,1 to 30,binary,count,114
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,pravastatin,1 to 30,binary,percentage,0.373293166115459
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,lovastatin,1 to 30,binary,count,35
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,lovastatin,1 to 30,binary,percentage,0.11460755100036
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,pitavastatin,1 to 30,binary,count,10
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,pitavastatin,1 to 30,binary,percentage,0.0327450145715315
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,ezetimibe,1 to 30,binary,count,208
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,ezetimibe,1 to 30,binary,percentage,0.681096303087855
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,fluvastatin,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,fluvastatin,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,cerivastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,cerivastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,unexposed,1 to 30,binary,count,29692
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,unexposed,1 to 30,binary,percentage,97.2264972657913
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,alirocumab,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,alirocumab,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,atorvastatin,31 to 90,binary,count,612
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,atorvastatin,31 to 90,binary,percentage,2.00399489177773
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,rosuvastatin,31 to 90,binary,count,252
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,rosuvastatin,31 to 90,binary,percentage,0.825174367202593
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,evolocumab,31 to 90,binary,count,14
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,evolocumab,31 to 90,binary,percentage,0.0458430204001441
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,pravastatin,31 to 90,binary,count,173
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,pravastatin,31 to 90,binary,percentage,0.566488752087495
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,pitavastatin,31 to 90,binary,count,15
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,pitavastatin,31 to 90,binary,percentage,0.0491175218572972
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,lovastatin,31 to 90,binary,count,57
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,lovastatin,31 to 90,binary,percentage,0.186646583057729
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,fluvastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,fluvastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,ezetimibe,31 to 90,binary,count,321
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,ezetimibe,31 to 90,binary,percentage,1.05111496774616
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,cerivastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,cerivastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,unexposed,31 to 90,binary,count,29121
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,unexposed,31 to 90,binary,percentage,95.3567569337568
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,lovastatin,91 to 180,binary,count,59
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,lovastatin,91 to 180,binary,percentage,0.193195585972036
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,rosuvastatin,91 to 180,binary,count,416
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,rosuvastatin,91 to 180,binary,percentage,1.36219260617571
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,alirocumab,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,alirocumab,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,fluvastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,fluvastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,ezetimibe,91 to 180,binary,count,396
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,ezetimibe,91 to 180,binary,percentage,1.29670257703265
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,evolocumab,91 to 180,binary,count,28
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,evolocumab,91 to 180,binary,percentage,0.0916860408002882
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,pitavastatin,91 to 180,binary,count,22
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,pitavastatin,91 to 180,binary,percentage,0.0720390320573693
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,pravastatin,91 to 180,binary,count,256
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,pravastatin,91 to 180,binary,percentage,0.838272373031206
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,atorvastatin,91 to 180,binary,count,923
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,atorvastatin,91 to 180,binary,percentage,3.02236484495236
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,cerivastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,cerivastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,unexposed,91 to 180,binary,count,28487
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,unexposed,91 to 180,binary,percentage,93.2807230099217
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,lovastatin,181 to 365,binary,count,73
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,lovastatin,181 to 365,binary,percentage,0.23903860637218
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,pitavastatin,181 to 365,binary,count,23
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,pitavastatin,181 to 365,binary,percentage,0.0753135335145224
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,ezetimibe,181 to 365,binary,count,423
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,ezetimibe,181 to 365,binary,percentage,1.38511411637578
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,rosuvastatin,181 to 365,binary,count,636
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,rosuvastatin,181 to 365,binary,percentage,2.0825829267494
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,evolocumab,181 to 365,binary,count,42
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,evolocumab,181 to 365,binary,percentage,0.137529061200432
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,alirocumab,181 to 365,binary,count,7
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,alirocumab,181 to 365,binary,percentage,0.022921510200072
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,fluvastatin,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,fluvastatin,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,atorvastatin,181 to 365,binary,count,1350
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,atorvastatin,181 to 365,binary,percentage,4.42057696715675
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,pravastatin,181 to 365,binary,count,314
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,pravastatin,181 to 365,binary,percentage,1.02819345754609
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,cerivastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,cerivastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,unexposed,181 to 365,binary,count,27789
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Female,unexposed,181 to 365,binary,percentage,90.9951209928288
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,number subjects,NA,numeric,count,29493
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,number records,NA,NA,count,29493
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,alirocumab,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,alirocumab,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,fluvastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,fluvastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,lovastatin,0 to 0,binary,count,5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,lovastatin,0 to 0,binary,percentage,0.0169531753297393
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,pitavastatin,0 to 0,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,pitavastatin,0 to 0,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,ezetimibe,0 to 0,binary,count,440
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,ezetimibe,0 to 0,binary,percentage,1.49187942901705
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,rosuvastatin,0 to 0,binary,count,12
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,rosuvastatin,0 to 0,binary,percentage,0.0406876207913742
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,atorvastatin,0 to 0,binary,count,45
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,atorvastatin,0 to 0,binary,percentage,0.152578577967653
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,pravastatin,0 to 0,binary,count,6
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,pravastatin,0 to 0,binary,percentage,0.0203438103956871
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,evolocumab,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,evolocumab,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,cerivastatin,0 to 0,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,cerivastatin,0 to 0,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,unexposed,0 to 0,binary,count,28983
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,unexposed,0 to 0,binary,percentage,98.2707761163666
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,atorvastatin,1 to 30,binary,count,387
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,atorvastatin,1 to 30,binary,percentage,1.31217577052182
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,evolocumab,1 to 30,binary,count,9
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,evolocumab,1 to 30,binary,percentage,0.0305157155935307
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,alirocumab,1 to 30,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,alirocumab,1 to 30,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,rosuvastatin,1 to 30,binary,count,200
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,rosuvastatin,1 to 30,binary,percentage,0.67812701318957
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,pravastatin,1 to 30,binary,count,69
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,pravastatin,1 to 30,binary,percentage,0.233953819550402
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,lovastatin,1 to 30,binary,count,13
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,lovastatin,1 to 30,binary,percentage,0.0440782558573221
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,pitavastatin,1 to 30,binary,count,10
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,pitavastatin,1 to 30,binary,percentage,0.0339063506594785
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,ezetimibe,1 to 30,binary,count,185
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,ezetimibe,1 to 30,binary,percentage,0.627267487200353
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,fluvastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,fluvastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,cerivastatin,1 to 30,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,cerivastatin,1 to 30,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,unexposed,1 to 30,binary,count,28637
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,unexposed,1 to 30,binary,percentage,97.0976163835486
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,alirocumab,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,alirocumab,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,atorvastatin,31 to 90,binary,count,608
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,atorvastatin,31 to 90,binary,percentage,2.06150612009629
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,rosuvastatin,31 to 90,binary,count,261
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,rosuvastatin,31 to 90,binary,percentage,0.884955752212389
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,evolocumab,31 to 90,binary,count,21
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,evolocumab,31 to 90,binary,percentage,0.0712033363849049
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,pravastatin,31 to 90,binary,count,120
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,pravastatin,31 to 90,binary,percentage,0.406876207913742
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,pitavastatin,31 to 90,binary,count,10
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,pitavastatin,31 to 90,binary,percentage,0.0339063506594785
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,lovastatin,31 to 90,binary,count,32
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,lovastatin,31 to 90,binary,percentage,0.108500322110331
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,fluvastatin,31 to 90,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,fluvastatin,31 to 90,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,ezetimibe,31 to 90,binary,count,348
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,ezetimibe,31 to 90,binary,percentage,1.17994100294985
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,cerivastatin,31 to 90,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,cerivastatin,31 to 90,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,unexposed,31 to 90,binary,count,28120
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,unexposed,31 to 90,binary,percentage,95.3446580544536
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,lovastatin,91 to 180,binary,count,37
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,lovastatin,91 to 180,binary,percentage,0.125453497440071
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,rosuvastatin,91 to 180,binary,count,451
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,rosuvastatin,91 to 180,binary,percentage,1.52917641474248
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,alirocumab,91 to 180,binary,count,6
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,alirocumab,91 to 180,binary,percentage,0.0203438103956871
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,fluvastatin,91 to 180,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,fluvastatin,91 to 180,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,ezetimibe,91 to 180,binary,count,375
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,ezetimibe,91 to 180,binary,percentage,1.27148814973044
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,evolocumab,91 to 180,binary,count,30
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,evolocumab,91 to 180,binary,percentage,0.101719051978436
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,pitavastatin,91 to 180,binary,count,18
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,pitavastatin,91 to 180,binary,percentage,0.0610314311870613
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,pravastatin,91 to 180,binary,count,154
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,pravastatin,91 to 180,binary,percentage,0.522157800155969
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,atorvastatin,91 to 180,binary,count,880
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,atorvastatin,91 to 180,binary,percentage,2.98375885803411
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,cerivastatin,91 to 180,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,cerivastatin,91 to 180,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,unexposed,91 to 180,binary,count,27594
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,unexposed,91 to 180,binary,percentage,93.561184009765
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,lovastatin,181 to 365,binary,count,31
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,lovastatin,181 to 365,binary,percentage,0.105109687044383
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,pitavastatin,181 to 365,binary,count,20
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,pitavastatin,181 to 365,binary,percentage,0.067812701318957
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,ezetimibe,181 to 365,binary,count,422
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,ezetimibe,181 to 365,binary,percentage,1.43084799782999
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,rosuvastatin,181 to 365,binary,count,686
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,rosuvastatin,181 to 365,binary,percentage,2.32597565524023
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,evolocumab,181 to 365,binary,count,38
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,evolocumab,181 to 365,binary,percentage,0.128844132506018
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,alirocumab,181 to 365,binary,count,8
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,alirocumab,181 to 365,binary,percentage,0.0271250805275828
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,fluvastatin,181 to 365,binary,count,<5
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,fluvastatin,181 to 365,binary,percentage,NA
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,atorvastatin,181 to 365,binary,count,1392
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,atorvastatin,181 to 365,binary,percentage,4.71976401179941
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,pravastatin,181 to 365,binary,count,209
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,pravastatin,181 to 365,binary,percentage,0.708642728783101
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,cerivastatin,181 to 365,binary,count,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,cerivastatin,181 to 365,binary,percentage,0
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,unexposed,181 to 365,binary,count,26795
PHARMETRICS,Summarise treatment,cohort_name,simvastatin,sex,Male,unexposed,181 to 365,binary,percentage,90.8520665920727
